The Biomimetic Extracellular Matrix: a Therapeutic Tool for Breast Cancer Research
Metadata
Show full item recordAuthor
Tamayo Angorrilla, Marta; López de Andrés, Julia; Jiménez González, Gema; Marchal Corrales, Juan AntonioEditorial
Elsevier
Date
2021-11-27Referencia bibliográfica
Marta Tamayo-Angorrilla... [et al.]. The biomimetic extracellular matrix: a therapeutic tool for breast cancer research, Translational Research, Volume 247, 2022, Pages 117-136, ISSN 1931-5244, [https://doi.org/10.1016/j.trsl.2021.11.008]
Sponsorship
Junta de Andalucia PIN-0224-2019; Convocatoria de Proyectos Intramurales ibs.GRANADA INTRAIBS-2020-10; Spanish Government RTI2018-101309-B-C22; Junta de Andalucia P18-FR-2470 SOMM17/6109/UGR; Ministry of Economy and Competitiveness, Instituto de Salud Carlos III PIE16/00045 DTS19/00143 DTS17/00087; Chair "Doctors GaleraRequena in cancer stem cell research" CMC-CTS963 Universidad de Granada/CBUAAbstract
Background: A deeper knowledge of the functional versatility and dynamic nature
of the ECM has improved the understanding of cancer biology.
Translational Significance: This work provides an in-depth view of the importance of
the ECM to develop more mimetic breast cancer models, which aim to recreate the
components and architecture of tumor microenvironment. Special focus is placed
on decellularized matrices derived from tissue and cell culture, both in procurement
and applications, as they have achieved great success in cancer research and
pharmaceutical sector.
The extracellular matrix (ECM) is increasingly recognized as a master regulator of
cell behavior and response to breast cancer (BC) treatment. During BC progression,
the mammary gland ECM is remodeled and altered in the composition and organization.
Accumulated evidence suggests that changes in the composition and
mechanics of ECM, orchestrated by tumor-stromal interactions along with ECM
remodeling enzymes, are actively involved in BC progression and metastasis.
Understanding how specific ECM components modulate the tumorigenic process
has led to an increased interest in the development of biomaterial-based biomimetic
ECM models to recapitulate key tumor characteristics. The decellularized
ECMs (dECMs) have emerged as a promising in vitro 3D tumor model, whose recent
advances in the processing and application could become the biomaterial by
excellence for BC research and the pharmaceutical industry. This review offers a
detailed view of the contribution of ECM in BC progression, and highlights the application
of dECM-based biomaterials as promising personalized tumor models that
more accurately mimic the tumorigenic mechanisms of BC and the response to
treatment. This will allow the design of targeted therapeutic approaches adapted to
the specific characteristics of each tumor that will have a great impact on the precision
medicine applied to BC patients. (Translational Research 2022; 247:117 136)